Beta Bionics (NASDAQ:BBNX) Director Sells $39,354.00 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX) Director Christy Jones sold 2,811 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $14.00, for a total value of $39,354.00. Following the sale, the director owned 27,400 shares in the company, valued at approximately $383,600. This trade represents a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christy Jones also recently made the following trade(s):

• On Thursday, May 21st, Christy Jones sold 1,998 shares of Beta Bionics stock. The stock was sold at an average price of $9.95, for a total value of $19,880.10.

Beta Bionics Stock Performance

BBNX stock remained flat at $13.89 during trading on Friday. The company had a trading volume of 1,006,729 shares, compared to its average volume of 1,142,134. The stock has a 50 day moving average price of $10.88 and a 200-day moving average price of $17.21. Beta Bionics, Inc. has a 1-year low of $8.80 and a 1-year high of $32.71. The firm has a market cap of $618.97 million, a PE ratio of -9.20 and a beta of 3.40.

Beta Bionics (NASDAQ:BBNX) last announced its earnings results on Tuesday, April 21st. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.04. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%.The business had revenue of $27.63 million for the quarter. Equities analysts expect that Beta Bionics, Inc. will post -2.19 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the company. The Goldman Sachs Group reduced their target price on Beta Bionics from $19.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. Truist Financial reduced their target price on Beta Bionics from $25.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, April 15th. UBS Group upgraded Beta Bionics to a “strong-buy” rating in a report on Monday, February 9th. Lake Street Capital set a $20.00 target price on Beta Bionics in a report on Wednesday, February 18th. Finally, Wall Street Zen lowered Beta Bionics from a “hold” rating to a “sell” rating in a research note on Sunday, March 29th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $19.70.

Hedge Funds Weigh In On Beta Bionics

A number of institutional investors have recently modified their holdings of BBNX. Charles Schwab Investment Management Inc. raised its holdings in Beta Bionics by 0.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 331,623 shares of the company’s stock worth $10,105,000 after buying an additional 931 shares during the last quarter. Deutsche Bank AG grew its holdings in shares of Beta Bionics by 3.4% during the fourth quarter. Deutsche Bank AG now owns 39,300 shares of the company’s stock valued at $1,197,000 after buying an additional 1,296 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Beta Bionics by 203.6% during the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after acquiring an additional 1,594 shares in the last quarter. Summit Securities Group LLC bought a new stake in shares of Beta Bionics during the fourth quarter worth about $52,000. Finally, Caitong International Asset Management Co. Ltd increased its position in shares of Beta Bionics by 1,075.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock worth $61,000 after acquiring an additional 1,818 shares in the last quarter.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.